Considerations for radiotherapy in Bloom Syndrome: A case series

M. H.D. Schoenaker*, S. Takada, M. van Deuren, C. J. Dommering, S. S.V. Henriët, I. Pico, W. V. Vogel, C. M.R. Weemaes, M. A.A.P. Willemsen, M. van der Burg, J. H.A.M. Kaanders

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Bloom Syndrome (BS) is a genetic DNA repair disorder, caused by mutations in the BLM gene. The clinical phenotype includes growth retardation, immunodeficiency and a strong predisposition to different types of malignancies. Treatment of malignancies in BS patients with radiotherapy or chemotherapy is believed to be associated with increased toxicity, but clinical and laboratory data are lacking. We collected clinical data of two Dutch BS patients with solid tumors. Both were treated with radiotherapy before the diagnosis BS was made and tolerated this treatment well. In addition, we collected fibroblasts from BS patients to perform in vitro clonogenic survival assays to determine radiosensitivity. BS fibroblasts showed less radiosensitivity than the severely radiosensitive Artemis fibroblasts. Moreover, studies of double strand break kinetics by counting 53BP1 foci after irradiation showed similar patterns compared to healthy controls. In combination, the clinical cases and laboratory experiments are valuable information in the discussion whether radiotherapy is absolutely contraindicated in BS, which is the Case in other DNA repair syndromes like Ataxia Telangiectasia and Artemis.

Original languageEnglish
Article number104293
JournalEuropean Journal of Medical Genetics
Issue number10
Publication statusPublished - Oct 2021

Cite this